The safety of statins in clinical practice.

By J. Armitage. The Lancet, 2007

814 citations recorded by the source corpus.

Subfields: Cell Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/1371218c397ae28e5548102cd26b66893c4043c1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. J. Armitage
2. George Davey Smith
3. R. Collins
4. M. Law
5. Judith Hochman
6. M. Creager
7. P. Ridker
8. J. Tobert

Citations in the corpus

• 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi (2011, background): “Nonetheless, the presence of active or hronic liver disease is a contraindication to statin use, and atients initiated on a statin should be monitored for the evelopment of myositis or rhabdomyolosis, either of which ould mandate its discontinuation (580).”
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013, background): “Niacin does not inhibit cytochrome P450 3A4 or interfere with statin-glucuronidation, but it has been found to increase simvastatin blood concentrations by about one-third,(24) and statin-induced myopathy is known to be associated with higher blood statin levels.(25) Asian subjects are also recogniz”
• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, background): “These muscle symptoms are typically bilateral and symmetrical and always confined to skeletal muscle.(33,34) Cardiomyopathy has never been associated with any statin, and in the 2 major trials of statin therapy in participants with heart failure, statins did not lead to symptomatic worsening of the ”
• GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. (2013, background): “Serious adverse effects were unusual, and all adverse effects were readily reversible with drug discontinuation [13].”
• Interpretation of the evidence for the efficacy and safety of statin therapy. (2016, background): “It usually resolves rapidly when statin therapy is stopped.(141)”
• Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015, neutral): “genetic factors, ethnicity, interacting drugs, and patient characteristics) (see Box 1).(30) Rhabdomyolysis is a”